AllianceBernstein
ELDN icon

AllianceBernstein’s Eledon Pharmaceuticals ELDN Stock Holding History

AllianceBernstein’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-285
Closed -$613K – 2958
2015
Q2 		$613K Buy
285
+276
+3,067% +$534K ﹤0.01% 2521
2015
Q1 		$16K Buy
+9
New +$19.9K ﹤0.01% 3296

Other funds holding ELDN

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein's ELDN Position: Q3 2015 in Review

AllianceBernstein sold out of Eledon Pharmaceuticals (ELDN) in Q3 2015, closing a stake of 285 shares — an estimated $613K sold.

AllianceBernstein first reported a position in ELDN in Q1 2015 and held it in 2 quarters. The position peaked at $613K in Q2 2015. 49 funds tracked by Wall St. Rank hold ELDN as of Q3 2015.

  • AllianceBernstein reported no remaining Eledon Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • AllianceBernstein sold 285 Eledon Pharmaceuticals shares in Q3 2015, an estimated $613K.
  • AllianceBernstein first reported a position in Eledon Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • AllianceBernstein's Eledon Pharmaceuticals position peaked at $613K in Q2 2015.
  • 49 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2015.

Based on AllianceBernstein's 13F filing for Q3 2015, filed 13 Nov 2015.